Clinical biomarkers in soft tissue sarcoma A comprehensive review of current soft tissue sarcoma biomarkers

Sharma, Soumya R; Paonessa, Nadia E; Casadei, Lucia; Faria, Fernanda; Pollock, Raphael E.; Grignol, Valerie

doi:10.1002/jso.26680

Cited by 7 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional factors that have been examined as potential genomic biomarkers in STS include circulating tumor DNA (ctDNA), microRNA, and the contents of extracellular vescicle cargo. With the potential to direct the administration of adjuvant chemotherapy, postoperative ctDNA is a particularly promising biomarker that has the potential to make a difference in the treatment of tumors [55]. Recent research indicates that neutrophil extracellular traps (NETs) play multiple roles in cancer-associated inflammation (Table 2).…”

Section: How To Improve Further Prognostication Of All Sarcomas: Inte...mentioning

confidence: 99%

Sarculator: how to improve further prognostication of all sarcomas

Borghi,

Gronchi

2024

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review Prognostication of soft tissue sarcomas is challenging due to the diversity of prognostic factors, compounded by the rarity of these tumors. Nomograms are useful predictive tools that assess multiple variables simultaneously, providing estimates of individual likelihoods of specific outcomes at defined time points. Although these models show promising predictive ability, their use underscores the need for further methodological refinement to address gaps in prognosis accuracy. Recent findings Ongoing efforts focus on improving prognostic tools by either enhancing existing models based on established parameters or integrating novel prognostic markers, such as radiomics, genomic, proteomic, and immunologic factors. Artificial intelligence is a new field that is starting to be explored, as it has the capacity to combine and analyze vast and intricate amounts of relevant data, ranging from multiomics information to real-time patient outcomes. Summary The integration of these innovative markers and methods could enhance the prognostic ability of nomograms such as Sarculator and ultimately enable more accurate and individualized healthcare. Currently, clinical variables continue to be the most significant and effective factors in terms of predicting outcomes in patients with STS. This review firstly introduces the rationale for developing and employing nomograms such as Sarculator, secondly, reflects on some of the latest and ongoing methodological refinements, and provides future perspectives in the field of prognostication of sarcomas.

show abstract

Section: How To Improve Further Prognostication Of All Sarcomas: Inte...mentioning

confidence: 99%

Sarculator: how to improve further prognostication of all sarcomas

Borghi,

Gronchi

2024

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

“…Diagnose and prognosis biomarkers are measurable properties that assist clinical oncology scientists in their first encounter with a patient with suspected cancer. 7 Such as early diagnosing, selecting the appropriate treatment method, and tracking response to therapy. 8 The prognostic biomarker is one that indicates progression or disease condition which predicts the upcoming clinical event of cancer.…”

Section: Types Of Biomarkersmentioning

confidence: 99%

An Overview of a Biomarker in Breast Cancer

Akhila,

Nagashree AG,

Spandana KM

et al. 2023

Int J. Pharm. Investigation

View full text Add to dashboard Cite

Cancer is one of the leading causes of death across the world, which is caused by tumours. Breast Cancer (BC) is the most common cancer in women and the second most common cancer death in women. A variety of molecular biomarkers are being used to predict BC susceptibility, including hormone receptors for subtyping and several genes involved in genome maintenance. Hence, biomarkers have specific importance in translational and clinical development to improve diagnosis, prognosis, and treatment since they have advantages in detection time and energy efficiency. The impact of breast cancer, as well as BC risk factors, identification of high-risk groups, screening modalities, and guidelines for screening average-risk and high-risk individuals, therapy advancement using various types of biomarkers. This review describes the design, approval, and distribution of biomarkers and outlines the many types of biomarkers currently used in breast cancer.

show abstract

“…The progress in our understanding of the immune components of STS has led to the development of immune checkpoint inhibitors, activated NK cells, and CART T cells, also illustrated in this review. The authors have taken one step further to outline the cellular, molecular and metabolic biomarkers [ 113 , 114 ]. To further personalize care based on molecular profiling, many randomized control trials are underway.…”

Section: Molecular Biology and Treatment Selectionmentioning

confidence: 99%

“…Notably, the MULTISARC (NCT03784014) is designed to randomize patients to undergo next generation sequencing of their tumor to then enter the phase II second-line targeted treatment to their genomic alternation. Furthermore, targeted therapies based on sarcoma subtype are outlined in a recent review [ 114 ].…”

Section: Molecular Biology and Treatment Selectionmentioning

confidence: 99%

Retroperitoneal Sarcoma Care in 2021

Schmitz

Nessim

2022

Cancers

View full text Add to dashboard Cite

Soft-tissue sarcomas are biologically heterogenous tumors arising from connective tissues with over 100 subtypes. Although sarcomas account for <1% of all adult malignancies, retroperitoneal sarcomas are a distinct subgroup accounting for <10% of all sarcomatous tumors. There have been considerable advancements in the understanding and treatment of retroperitoneal sarcoma in the last decade, with standard treatment consisting of upfront primary surgical resection. The evidence surrounding the addition of radiation therapy remains controversial. There remains no standard with regards to systemic therapy, including immunotherapy. Adjunctive therapy remains largely dictated by expert consensus and preferences at individual centers or participation in clinical trials. In this 2021 review, we detail the anatomical boundaries of the retroperitoneum, clinical characteristics, contemporary standard of care and well as recent advancements in retroperitoneal sarcoma care. Ongoing international collaborations are encouraged to advance our understanding of this complex disease.

show abstract

Clinical biomarkers in soft tissue sarcoma A comprehensive review of current soft tissue sarcoma biomarkers

Cited by 7 publications

References 36 publications

Sarculator: how to improve further prognostication of all sarcomas

Sarculator: how to improve further prognostication of all sarcomas

An Overview of a Biomarker in Breast Cancer

Retroperitoneal Sarcoma Care in 2021

Contact Info

Product

Resources

About